PKN605

Phase 2Small molecule

Novartis

PKN605 is one of 52 small molecule programs targeting Renal Impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal ImpairmentNot yet recruiting

Atrial FibrillationRecruiting

Renal ImpairmentPhase 1

Not yet recruiting

Atrial FibrillationPhase 2

Recruiting

Competition

Competitive Landscape

137 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Calquence

AstraZeneca

Preclinical

1 2

Rituxan

Coumadin

3 4

PKN605

Novartis

Phase 2

1 5

Imbruvica

PPharmacyclics LLC.

Preclinical

1 6

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 8

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Brukinsa

BBeOne Medicines

Preclinical

1 10

SGLT2 Inhibitor

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Renal Impairment

NCT07797322

Q3 2027

Phase 2Recruiting

Atrial Fibrillation

NCT07217067

Clinical

Trials by Indication[1]

Renal Impairment1 trial

A Phase 1, Single-dose, Open-label Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Participants With Normal Renal Function

Not yet recruiting· Novartis logo

Novartis·Phase 1·NCT07797322·40 enrolled

Atrial Fibrillation1 trial

A Randomized, Placebo-controlled, Participant- and Investigator-blinded Study to Evaluate the Efficacy in Reducing Atrial Fibrillation Burden (AFB) as Well as the Safety, Tolerability, and Pharmacokinetics of Oral PKN605 in Participants With Atrial Fibrillation

Recruiting· Novartis logo

Novartis·Phase 2·NCT07217067·165 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PKN605. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PKN605 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PKN605. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

PKN605

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Renal Impairment1 trial

Atrial Fibrillation1 trial

References

Drug Info

Quick Facts

Related News